Financial highlights / cash outflow FY18
- 12+ months of cash at hand
- Potential for further payments of the following:
- AGC milestone payments – potential US$5m
- Share of licence fees from licensing clinical development and marketing rights of Progenza for OA and other indications in Japan
- Licences of other clinical assets
In summary, cash outflow conscious, spending tight and related to necessary business development.
Long term hold.
Ann: FY17 Results Presentation, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
